Hypha Labs, Inc. (FUNI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hypha Labs, Inc. (FUNI) trades at $0.02 with AI Score 42/100 (Grade C). Hypha Labs, Inc. Market cap: $2.56M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for FUNI: FUNI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FUNI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FUNI: the 1 perspectives are evenly split.
How is this calculated? →Hypha Labs, Inc. (FUNI) Healthcare & Pipeline Overview
Hypha Labs, Inc. is a development-stage company focused on the Hypha Micropearl bioreactor, a home appliance designed for accelerated mushroom production. Operating in the medical diagnostics and research industry, the company aims to capitalize on the growing interest in functional foods and home-based health solutions, though it faces significant challenges in commercialization and market adoption.
What Is the Investment Thesis for FUNI?
Hypha Labs, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on the Hypha Micropearl bioreactor targets a niche market within the functional foods and home wellness sectors. However, with a market capitalization of $2.56M and a negative P/E ratio of -1.91, the company's financial viability is uncertain. Key growth catalysts include successful commercialization of the Hypha Micropearl bioreactor and expansion into new markets. The primary risk lies in the company's ability to secure funding, achieve profitability, and compete with established players in the health and wellness industry. Investors should carefully consider the company's limited operating history and the speculative nature of its business model.
Based on FMP financials and quantitative analysis
FUNI Key Highlights
- Hypha Labs, Inc. operates in the medical diagnostics and research industry, focusing on home-based bioreactor technology.
- The company's primary product is the Hypha Micropearl bioreactor, designed for accelerated production of beneficial mushrooms.
- Hypha Labs, Inc. has a market capitalization of $2.56M, indicating a micro-cap company with high growth potential but also high risk.
- The company's P/E ratio is -1.91, reflecting current losses and the need for future profitability.
- The company has a beta of 1.28, indicating that the stock is more volatile than the market average.
Who Are FUNI's Competitors?
FUNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FUNI's Key Strengths?
- Innovative bioreactor technology.
- Focus on a growing market segment.
- Potential for recurring revenue through subscriptions.
What Are FUNI's Weaknesses?
- Limited operating history.
- Small team and limited resources.
- Dependence on a single product.
What Could Drive FUNI Stock Higher?
- Successful commercialization of the Hypha Micropearl bioreactor.
- Partnerships with health and wellness companies.
- Development of new bioreactor applications.
- Expansion into new markets.
What Are the Key Risks for FUNI?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources.
- Competition from established players.
- Regulatory hurdles.
- Market acceptance of home-based cultivation.
- Dependence on a single product.
What Are the Growth Opportunities for FUNI?
- Expansion into New Markets: Hypha Labs has the opportunity to expand its market reach beyond the United States. The global market for functional foods is projected to reach $278 billion by 2028, presenting a significant opportunity for Hypha Labs to introduce its Hypha Micropearl bioreactor to international consumers. Timeline: 2027-2029.
- Partnerships with Health and Wellness Companies: Hypha Labs can pursue strategic partnerships with established health and wellness companies to expand its distribution network and increase brand awareness. Collaborating with companies that offer complementary products or services can provide access to a wider customer base and accelerate market penetration. Timeline: Ongoing.
- Development of New Bioreactor Applications: Hypha Labs can leverage its bioreactor technology to develop new applications beyond mushroom cultivation. This could include bioreactors for producing other beneficial foods or supplements, catering to a broader range of health and wellness needs. The market for personalized nutrition solutions is expected to grow significantly in the coming years. Timeline: 2028-2030.
- Subscription-Based Service Model: Hypha Labs can implement a subscription-based service model, offering customers ongoing access to mushroom spores, nutrients, and educational resources. This recurring revenue stream can provide a stable financial foundation and foster long-term customer relationships. The subscription model aligns with the growing trend of personalized health and wellness services. Timeline: 2027.
- Integration with Smart Home Technology: Hypha Labs can integrate its Hypha Micropearl bioreactor with smart home technology, allowing users to monitor and control the bioreactor remotely. This integration can enhance the user experience and appeal to tech-savvy consumers who are increasingly adopting smart home devices. The smart home market is projected to reach $622 billion by 2026. Timeline: 2028.
What Opportunities Does FUNI Have?
- Expansion into new markets.
- Partnerships with health and wellness companies.
- Development of new bioreactor applications.
What Threats Does FUNI Face?
- Competition from established players.
- Regulatory hurdles.
- Market acceptance of home-based cultivation.
What Are FUNI's Competitive Advantages?
- Proprietary bioreactor technology.
- First-mover advantage in the home-based mushroom cultivation market.
- Potential for brand recognition in the emerging market.
What Does FUNI Do?
Hypha Labs, Inc., incorporated in 2010 and headquartered in Las Vegas, Nevada, is dedicated to the research, development, and commercialization of the Hypha Micropearl bioreactor. This innovative home appliance is designed to accelerate the production of beneficial mushrooms for human consumption. The company's core focus is on providing a convenient solution for individuals seeking to cultivate and consume functional foods at home. The Hypha Micropearl bioreactor represents the company's primary offering, targeting health-conscious consumers interested in incorporating mushrooms with potential health benefits into their diets. Hypha Labs aims to position itself as a leader in the emerging market for home-based bioreactor technology, catering to the growing demand for personalized nutrition and wellness solutions. However, the company is still in its early stages of commercialization and faces the challenge of establishing market acceptance and scaling production. With a small team of 5 employees, Hypha Labs is currently led by A. Stone Douglass. The company's success hinges on its ability to effectively market and distribute the Hypha Micropearl bioreactor, as well as to demonstrate the value proposition of home-based mushroom cultivation to a broad consumer base. The company operates exclusively in the United States.
What Products and Services Does FUNI Offer?
- Researches and develops bioreactor technology.
- Commercializes the Hypha Micropearl bioreactor.
- Offers a home appliance for accelerated mushroom production.
- Targets health-conscious consumers.
- Focuses on functional foods and personalized nutrition.
- Aims to provide a convenient solution for home-based cultivation.
How Does FUNI Make Money?
- Sales of Hypha Micropearl bioreactors to consumers.
- Potential subscription model for spores and nutrients.
- Partnerships with health and wellness companies for distribution.
What Industry Does FUNI Operate In?
Hypha Labs, Inc. operates within the medical diagnostics and research industry, specifically targeting the intersection of functional foods and home-based health solutions. The market for functional foods is experiencing growth, driven by increasing consumer awareness of health and wellness. However, the competitive landscape includes established players in the health appliance and mushroom cultivation sectors. Hypha Labs faces the challenge of differentiating its product and establishing a strong market presence in a rapidly evolving industry. The company's success depends on its ability to capitalize on emerging trends in personalized nutrition and home-based health technologies.
Who Are FUNI's Key Customers?
- Health-conscious consumers.
- Individuals interested in functional foods.
- People seeking home-based health solutions.
How Hypha Labs, Inc. Is Valued
Hypha Labs, Inc. carries a market capitalization of $2.56M, placing it in the micro-cap category. Relative to its peer group, FUNI's quantitative score of 42/100 is below the peer average of 64/100.
ROE 96%Key Financial Metrics
Return on equity for Hypha Labs, Inc. stands at 96.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -26.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -104.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Hypha Labs, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FUNI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Hypha Labs insiders seem to be showing confidence, with recent activity suggesting they believe in the company's long-term prospects. This contrasts with some of the negative chatter we've been hearing.
- The community is buzzing about potential partnerships that could significantly expand Hypha Labs' market reach. If these materialize, it could be a game-changer.
- There's a growing sense that the market is undervaluing Hypha Labs' intellectual property. If this perception shifts, we could see a substantial re-rating.
- Despite the recent volatility, there's still a strong undercurrent of belief in Hypha Labs' core technology and its potential to disrupt the industry.
Bear Case
- The overall market sentiment towards growth stocks has been shaky lately, and Hypha Labs could get caught in the crossfire regardless of its fundamentals.
- The community's been voicing concerns about increasing competition in Hypha Labs' sector. This could put pressure on margins and market share.
- Some traders are worried about potential regulatory headwinds that could impact Hypha Labs' ability to operate in certain markets. This uncertainty is weighing on the stock.
- Despite the insider buying, there's a lingering feeling that Hypha Labs is struggling to translate its innovative ideas into tangible revenue growth. This execution risk is a major concern.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FUNI Latest News
No recent news available for FUNI.
FUNI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FUNI.
Price Targets
Wall Street price target analysis for FUNI.
FUNI MoonshotScore
What does this score mean?
The MoonshotScore rates FUNI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: A. Stone Douglass
CEO
A. Stone Douglass is the CEO of Hypha Labs, Inc., managing a small team of 5 employees. Information regarding A. Stone Douglass's detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background cannot be provided.
Track Record: Due to limited information, A. Stone Douglass's key achievements, strategic decisions, and company milestones under their leadership cannot be accurately assessed. Further data is needed to evaluate their track record at Hypha Labs, Inc.
FUNI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hypha Labs, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware of the increased risks associated with investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited liquidity and trading volume.
- Less stringent regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any legal or regulatory actions against the company.
- Company incorporation in 2010 suggests some operational history.
- Focus on a specific product (Hypha Micropearl bioreactor) indicates a defined business strategy.
- Presence of a CEO (A. Stone Douglass) suggests leadership structure.
FUNI Healthcare Stock FAQ
What does Hypha Labs, Inc. do?
Hypha Labs, Inc. is focused on the development and commercialization of the Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. The company aims to provide a convenient solution for individuals seeking to cultivate and consume functional foods at home, targeting the growing market for personalized nutrition and wellness solutions. The company operates primarily in the United States.
What are the main risks for FUNI?
The main risks for Hypha Labs, Inc. include its limited operating history, small team and resources, and dependence on a single product. The company faces competition from established players in the health and wellness industry, as well as regulatory hurdles related to the commercialization of its bioreactor technology. Market acceptance of home-based mushroom cultivation is also a significant risk. Additionally, as an OTC-listed company, FUNI is subject to less stringent regulatory oversight and higher risk of price volatility.
How does Hypha Labs, Inc. navigate regulatory approval processes?
As Hypha Labs, Inc. focuses on a home appliance for mushroom cultivation, the regulatory approval processes may differ from those of pharmaceutical or medical device companies. However, the company must still comply with relevant food safety regulations and ensure that its product meets safety standards. Specific details regarding Hypha Labs, Inc.'s regulatory track record and compliance strategy are not available in the provided data. Further research is needed to assess the company's approach to regulatory compliance.
What revenue streams does Hypha Labs, Inc. have in healthcare?
Hypha Labs, Inc.'s primary revenue stream is expected to come from the sale of its Hypha Micropearl bioreactor. The company may also generate revenue through a subscription-based service model, offering customers ongoing access to mushroom spores, nutrients, and educational resources. Specific details regarding Hypha Labs, Inc.'s revenue breakdown by product line, therapeutic area, and geographic market are not available in the provided data. Further information is needed to assess the company's revenue diversification and growth potential.
What are the key factors to evaluate for FUNI?
Hypha Labs, Inc. (FUNI) holds an AI score of 42/100 (low). Not financial advice.
How frequently does FUNI data refresh on this page?
FUNI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FUNI's recent stock price performance?
Hypha Labs, Inc. (FUNI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative bioreactor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FUNI overvalued or undervalued right now?
Valuing Hypha Labs, Inc. (FUNI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for Hypha Labs, Inc.
- OTC market investments carry higher risk.
- AI analysis pending, further insights may be available later.